Schedule an Appointment


Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

Book a Conference Call
Get More Information

Wellesley Pharmaceuticals

Location: Newtown, PA

Sector: Life Sciences


Add to Shortlist
Express Interest

Wellesley Pharmaceuticals, LLC was founded to ensure that the ability of Nocturol™ to reduce and sometimes eliminate nocturia symptoms can be disseminated to help the hundreds of millions of people who can benefit from it.   Nocturol is a drug to treat nocturia, the frequent need to urinate at night.  This sometimes-deadly condition afflicts 2.4 billion people and causes insomnia, fatigue, depression, lower quality of life, higher rates of heart disease, stroke, long term brain damage, and deadly falls.

Business Documents

MG cp Summary

Huge unmet medical need – 2.4 billion people suffer from nocturia, which causes insomnia, fatigue, depression, lower quality of life, higher rates of heart disease, stroke, long term brain damage and deadly falls.


No viable competition – There is one FDA approved drug to treat nocturia and it demonstrated a 0.2 void/night benefit compared to the placebo.  Our result was 4.5 times better than that. Their drug has a black box warning about the dangers of hyponatremia.  We had zero side effects reported even among patients using 2 or 3 times the recommended dose.


Strong patent portfolio – Our patent lawyer had been named one of the top 1000 patent lawyers in the world six years in a row.  Dr. Ping Wang has never had a patent even challenged, much less overturned.  Our patents include doses ranging from 5mg (which is useless) to 2000mg (which could be deadly).  We believe we have a huge wall of IP around our invention.

Instant efficacy – Our drug is to be taken 30 minutes before bedtime since it is effective in 30 minutes.


Lack of side effects – We are using about 20% of the recommended daily dose of the two component drugs for a 10-year-old child.  If it is safe for a 10-year-old to take 5 times per day, we think it should be very safe for most adults to take once per night.


Superior efficacy – Compared to placebo, our clinical trial demonstrated 4.5 times higher efficacy than the only FDA approved drug for nocturia.


High profit margins – As an LLC, we pay no corporate income tax.  As a virtual corporation, we have almost no overhead expenses.  We have only one full time employee.  We expect net income margins to approach 95% of revenue.

David A. Dill, CEO and President

David Dill is the inventor of Nocturol and the founder of Wellesley Pharmaceuticals, LLC.  Nine years ago he made six changes in his life and since then has over 100 inventions.  When he realized that one of them could have a major impact on the world, he left his CFO position to focus fulltime on nocturia, which killed his father-in-law and leads to thousands of deaths per day.   He graduated summa cum laude from Princeton University in 1973 with a degree in economics.  He graduated from MIT’s Sloan School of Management in 1975 with a Master’s degree in finance and marketing.   He spent 19 years at IBM rising to CFO of a $2 billion business unit.  Since then he was VP Finance at General Instrument and CFO at 7 venture backed companies in 7 different industries, including Worldgate Communications, PlasticsNet, StorageApps, Digital 5, Telewares, Orchestria, and Undertone.   Key Career Milestones Achieved: One IPO (Worldgate Communications in 1999), one sale of a company for $350 million (StorageApps sold to HP in 2001), over 100 inventions in the last 9 years.